Bioyond Tech is a technology company.
奔曜科技致力于生命科学领域智能自动化变革，利用机器人、自动化、人工智能等技术，为实验室提供易于部署的智能自动化产品及解决方案。
Bioyond Tech has raised $8.0M across 1 funding round.
Bioyond Tech has raised $8.0M in total across 1 funding round.
Bioyond Tech has raised $8.0M in total across 1 funding round.
Bioyond Tech's investors include Qiming Venture Partners.
Bioyond Tech (also known as Bioyond Robotics) is a Shanghai-based life sciences automation company founded in 2021 that develops modular robotics and AI-driven solutions to streamline laboratory workflows.[1][2][3] It serves research labs, clinical diagnostics facilities, and enterprises in drug screening, chemistry, biological engineering, and materials science by addressing high automation costs, skilled personnel shortages, and repetitive tasks through unattended operations, improved experimental consistency, and flexible systems.[1][2] The company has raised $36.94M in Series A-III funding, employs over 100 people (70% in R&D), and has served more than 100 clients with platforms in robotics, automation, data, and cloud technologies.[1][3]
Bioyond Tech was founded in March 2021 in Pudong (Shanghai Zhangjiang Science City), China, by a team of executives from Fortune 500 companies in robotics and life sciences, bringing deep scientific research backgrounds and product development experience.[1][3] The idea emerged from the need to transform intelligent automation in life sciences, leveraging the founders' expertise to create user-friendly robotics, vision, and AI solutions that free scientists from repetitive lab tasks.[3] Early traction came quickly, with the company establishing three core platforms (robotics, automation, data/cloud) and expanding to local teams in Europe and the U.S., while securing significant funding and serving over 100 prominent life sciences firms.[1][3]
Bioyond Tech rides the wave of AI-robotics convergence in life sciences, capitalizing on surging demand for lab automation amid global R&D acceleration in drug discovery, biologics, cell/gene therapy, and synthetic biology.[1][3] Timing is ideal post-2021 founding, aligning with post-pandemic biotech booms, labor shortages in skilled lab work, and AI advancements enabling precise, scalable workflows—market forces like rising drug development costs (often billions per candidate) favor cost-reducing automation.[1][2] It influences the ecosystem by empowering 100+ enterprises, fostering innovation in small molecule drugs, clinical diagnostics, and materials science, while its modular approach democratizes access for smaller labs, potentially accelerating breakthroughs in healthcare and beyond.[1][3]
Bioyond Tech is poised for hypergrowth, building on $36.94M funding and Series A-III momentum to expand its client base and product lines amid exploding life sciences automation demand.[1] Trends like AI-driven precision medicine, synthetic biology scale-up, and global lab digitization will propel it, with potential for international partnerships via its U.S./Europe teams.[3] Influence may evolve toward platform dominance, integrating deeper cloud analytics for end-to-end R&D, ultimately liberating scientists worldwide—just as its mission promises, transforming Bioyond from lab enabler to healthcare innovator.[1][3]
Bioyond Tech has raised $8.0M across 1 funding round. Most recently, it raised $8.0M Seed in October 2021.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Oct 1, 2021 | $8.0M Seed | Qiming Venture Partners |